Pricing Log in Create free account
Friday 6 November 2026 Export ACAD’s income statement to Excel — free account

ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.

Revenue
+22.9%
EPS
−27.9%
Free cash flow
+141.2%

Quarter to September 2026, against a year earlier

21.23 0.01 −0.05%
Market cap
$3.7B
P/E
10.0×
Fwd P/E
33.4×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

ACADIA Pharmaceuticals Inc. (ACAD) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, ACADIA Pharmaceuticals Inc. (ACAD) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from 1.7× (April 2025) to 70,999× (July 2015); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.4× 43.85%
FY2024 2.4× (62.46%)
FY2023 6.4× 47.94%
FY2022 4.3× (35.52%)
FY2021 6.7× (62.17%)
FY2020 17.6× 6.63%
FY2019 16.5× 134.91%
FY2018 7.0× (74.09%)
FY2017 27.1× (83.23%)
FY2016 162× (99.71%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 2.1× (30.04%)
Jun 2026 3.0× 10.59%
Mar 2026 2.7× (21.67%)
Dec 2025 3.4× 30.39%
43 more quarters

Against its own ten years

Low 1.7× High 70,999×
Ten-year median 9.7×
Current reading's percentile 4

EV/Sales against peers

Company EV/Sales
VKTX Viking Therapeutics, Inc. compare n/m
PBLS Parabilis Medicines, Inc. compare n/m
IRON Disc Medicine, Inc. compare n/m
DYN Dyne Therapeutics, Inc. compare n/m
ACAD ACADIA Pharmaceuticals Inc. 2.2×
IOVA Iovance Biotherapeutics, Inc. compare 8.5×
TNGX Tango Therapeutics, Inc. compare 34.7×
XENE Xenon Pharmaceuticals Inc. compare 169×
RLAY Relay Therapeutics, Inc. compare 231×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ACAD